We have heard for a period of time that the future of cancer treatment is in genetics. Despite the hubbub, we see very little hard evidence of this in today’s current treatment decisions. Treatment still remains tied into protocols with a strong bias to following a common map. Each map does have little variances, but [...]
Results from a recent international randomized phase II trial for the drug tasquinimod (TASQ), shows that TASQ is a potential therapy for men with advanced prostate cancer. The men who received TASQ on average went twice as long without disease progression as those who received only a placebo. […]
The House Appropriations Committee released revised subcommittee allocations yesterday for FY 2011. The new FY 2011 Labor-HHS-Education Subcommittee allocation is $157.02 billion, which is nearly $6.6 billion (4 percent) below the subcommittee’s FY10 allocation. The House is scheduled to vote on a FY11 appropriations bill during the week of February 14. Specific funding levels and [...]
Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]
On Thursday the Senate Appropriations subcommittee on Labor, Health and Human Services, and Education held its FY 2010 NIH budget hearing. There were two particular items of note for the cancer community. When discussing the NIH funding which was received through the economic stimulus package, Senator Harkin questioned if the current two years the NIH [...]